title: Misoprostol for abortion at 9-12 weeks' gestation in adolescents.
abstract: The objectives of the present clinical study were to evaluate the safety and efficacy of misoprostol (Cytotec), self-administered into the vagina for medical abortion, in adolescents under 18 years ofage. A group of 150 adolescents with gestations between 63 and 84 days, with previous written consent from the patient and parents or guardians, received 800 microg of vaginal misoprostol every 24 h, up to a maximum of three main doses, for abortion. Outcomes assessed included successful abortion (complete abortion without surgery), side-effects, decrease in hemoglobin, mean time of vaginal bleeding, mean expulsion time and mean time for the return of menses. Complete abortion occurred in 126/150 (84.0%, 95% confidence interval 77-89) patients. The frequencies of nausea and vomiting were statistically significantly higher when compared to those obtained for adult females. Vaginal bleeding lasted for 13.2 +/- 3.8 days (median 13 days, range 1-22 days). The mean expulsion time was 8.0 +/- 3.4 h (median 8 h, range 1-14 h) for all subjects who aborted after the first misoprostol dose. The mean drop in hemoglobin was statistically significant (p = 0.001), but without clinical relevance. From the high abortion rate obtained, we concluded that misoprostol alone is a valid method for terminating unwanted pregnancies at 10-13 weeks' gestation in adolescents under 18 years of age in the absence of mifepristone.
authors.affiliation: Clínca Mediterrania Medica, Valencia, Castelló, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Carbonell
authors.forename: A
authors.initials: A
authors.lastname: Velazco
authors.forename: L
authors.initials: L
authors.lastname: Varela
authors.forename: R
authors.initials: R
authors.lastname: Tanda
authors.forename: C
authors.initials: C
authors.lastname: Sánchez
authors.forename: S
authors.initials: S
authors.lastname: Barambio
authors.forename: S
authors.initials: S
authors.lastname: Chami
authors.forename: F
authors.initials: F
authors.lastname: Valero
authors.forename: S
authors.initials: S
authors.lastname: Aragón
authors.forename: J
authors.initials: J
authors.lastname: Marí
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects*; D000028:Abortion, Induced; D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects*; D009325:Nausea / Q000139:chemically induced; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011253:Pregnancy in Adolescence; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol